RxDoctor Payments Data

William Hill, MD

Ophthalmology · Mountain Home, ARNPI 1659414662

Payments from drug & device makers

$662in general payments, 2019–2025

Across 28 payments — averaging $23.65 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$154
  • Genentech USA, Inc.$103
  • Bausch & Lomb, A Division Of Bausch Health US, LLC$100
  • Regeneron Healthcare Solutions, Inc.$95
  • Sun Pharmaceutical Industries Inc.$46
  • Biotissue Holdings Inc.$44
  • plus $121 from 7 others

What the payments were for

  • Food & beverage$662100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$662 in reported general payments places this provider in the 45th percentile of 125 ophthalmology providers in Arkansas.

See all ophthalmology providers in Arkansas

Medicare billing

Part B allowed, 2024
$1,493,258
Medicare patients
1,467
Services billed
12,731

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
LumiganBimatoprost20$15,633
IlevroNepafenac37$13,635
CombiganBrimonidine Tartrate/Timolol29$11,368
RestasisCyclosporine12$9,599
RocklatanNetarsudil Mesylat/Latanoprost20$7,597
Latanoprost498$6,601
Brimonidine Tartrate148$6,193
Travoprost18$3,356
Prednisolone Acetate87$3,261
Timolol Maleate236$3,204
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat74$1,947
MoxifloxacinMoxifloxacin Hcl66$1,705
ValacyclovirValacyclovir Hcl26$1,006
ErythromycinErythromycin Base75$888
Dorzolamide Hcl46$789

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieLumigan, Combigan, Restasis$154$36,60161 claims
NovartisIlevro$18$13,63537 claims
Aerie Pharmaceuticals, Inc.Rocklatan$16$7,59720 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 45th percentile of 125 ophthalmology providers in Arkansas.

Other ophthalmology in Mountain Home

See the full list for Arkansas

Where these figures come from

Is this you, or does something look wrong? →